NCT/Study#

NCT04849273 /

TPX-0131-01

A PHASE 1/2 STUDY OF TPX-0131, A NOVEL ORAL ALK TYROSINE KINASE INHIBITOR IN SUBJECTS WITH ALK+ ADVANCED OR METASTATIC NSCLC

A PHASE 1/2 STUDY OF TPX-0131, A NOVEL ORAL ALK TYROSINE KINASE INHIBITOR IN SUBJECTS WITH ALK+ ADVANCED OR METASTATIC NSCLC

DISEASE GROUP:
Phase 1
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: